Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VXCO-100 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| VXC0-100 at Dose level 1 | EXPERIMENTAL | Participants will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 1 on Month 6. |
| VXC0-100 at Dose level 2 | EXPERIMENTAL | Participants will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 2 on Month 6. |
| VXC0-100 at Dose level 3 | EXPERIMENTAL | Participants will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 3 on Month 6. |
| COVID-19 mRNA vaccine | EXPERIMENTAL | Participants will receive a COVID-19 mRNA vaccine on Day 1 and then a boost with the same COVID-19 mRNA vaccine at Day 21. |
| VXCO-100 Group 1 | EXPERIMENTAL | Participants 18-55 years of age will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection |
| VXCO-100 Group 2 | EXPERIMENTAL | Participants 18-55 years of age will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection |
| VXCO-100 Group 3 | EXPERIMENTAL | Participants 18-55 years of age will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection |
| VXCO-100 Group 4 | EXPERIMENTAL | Participants 56+ years of age will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection |
| VXCO-100 Group 5 | EXPERIMENTAL | Participants 56+ years of age will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection |
| VXCO-100 Group 6 | EXPERIMENTAL | Participants 56+ years of age will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection |
| Name | Type | Description |
|---|---|---|
| VXCO-100 | BIOLOGICAL | Sterile suspension for injection |
| COVID-19 mRNA vaccine | BIOLOGICAL | Sterile suspension for injection |
Inclusion Criteria: A participant must meet all the following criteria to be eligible for the study: 1. Adults ages 18 years and older 2. Judged by the investigator to be healthy based on participant-reported medical history, physical examination, vital signs, and laboratory assessment. 3. Able to...
VXCO-100 is an investigational monoclonal antibody developed by Eli Lilly and Company for SARS-CoV, the virus that causes COVID-19. It is in Phase 1 clinical development and has been studied in healthy adult volunteers. Both of its Phase 1 trials have been completed.
VXCO-100 is being developed for SARS-CoV and SARS-CoV-2, the coronaviruses responsible for COVID-19. Its clinical program has focused on healthy adult volunteers rather than patients with active disease. It remains investigational and is not an approved product.
VXCO-100 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored both Phase 1 trials of the candidate, one conducted in the United States and one in the Republic of South Africa.
VXCO-100 is in Phase 1 clinical development. Both of its Phase 1 trials are listed as completed, and no trials are currently active. It is an investigational monoclonal antibody and has not been approved by the FDA for any indication.
VXCO-100 has been evaluated in two completed Phase 1 trials. NCT05870839 enrolled 121 healthy adults in the United States, and NCT05938075 enrolled 130 adults in the Republic of South Africa. Together the two randomized, controlled studies enrolled 251 participants aged 18 years and older.
VXCO-100 is a monoclonal antibody directed against SARS-CoV. Monoclonal antibodies are designed to bind a specific viral target, and this candidate was studied as a SARS-CoV vaccine approach in healthy adult volunteers. Detailed target and mechanism information has not been publicly characterized beyond its monoclonal antibody modality.